Anacor Pharmaceuticals, Inc. (ANAC) to Hold Conference Call Tomorrow, March 21, 2013 at 8am ET / 5am PT to Discuss Preliminary Results From the Phase 2 Dose-Ranging Study of AN2728 in the Treatment of Adolescents With Atopic Dermatitis
3/21/2013 11:23:02 AM
PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the Phase 2 dose-ranging study of AN2728 in the treatment of adolescents with atopic dermatitis tomorrow, March 21, 2013 at approximately 7:00 a.m. ET. The announcement will be followed by a conference call at 8:00 a.m. ET to discuss the results. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company’s website at www.anacor.com and will be available for three months following the call.